Evidence mapPaperPMID 40423973Full record

ArticleJAMA network open2025

Weight Loss in Midlife, Chronic Disease Incidence, and All-Cause Mortality During Extended Follow-Up.

Timo E Strandberg, Arto Y Strandberg, Satu Jyväkorpi, Annele Urtamo, Solja T Nyberg, Philipp Frank, Jaana Pentti, Kaisu H Pitkälä, Mika Kivimäki

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Six-year Follow-Up of Nonpharmacological and Nonsurgical Obesity Treatments.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Timo E StrandbergUniversity of Helsinki, Helsinki, Finland.
Arto Y StrandbergUniversity of Helsinki, Helsinki, Finland.
Satu JyväkorpiUniversity of Helsinki, Helsinki, Finland.
Annele UrtamoUniversity of Helsinki, Helsinki, Finland.
Solja T NybergClinicum, University of Helsinki, Helsinki, Finland.
Philipp FrankBrain Sciences, University College London, London, United Kingdom.
Jaana PenttiClinicum, University of Helsinki, Helsinki, Finland.
Kaisu H PitkäläUniversity of Helsinki, Helsinki, Finland.
Mika KivimäkiClinicum, University of Helsinki, Helsinki, Finland.

Funding

Medical Research CouncilNIA NIH HHS R01 AG056477Wellcome Trust
6 · The paper itself

Abstract

Importance: Few studies have examined long-term health benefits among individuals with sustained weight loss beyond its association with decreased diabetes risk. Objective: To examine the long-term association of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) changes during healthy midlife (ages 40-50 years) with later-life morbidity and mortality. Design, Setting, and Participants: This cohort study analyzed data from 3 cohorts that included repeated height and weight measurements: the Whitehall II study (WHII; baseline, 1985-1988), Helsinki Businessmen Study (HBS; baseline, 1964-1973), and Finnish Public Sector study (FPS; baseline, 2000). Participants were categorized into 4 groups based on their first 2 weight assessments and followed up for morbidity and mortality outcomes. Data analyses were conducted between February 11, 2024, and February 20, 2025. Exposures: Midlife BMI change was categorized as persistent BMI less than 25, BMI change from 25 or greater to less than 25, BMI change from less than 25 to 25 or greater, and persistent BMI of 25 or greater. Main Outcomes and Measures: Incident chronic disease, including type 2 diabetes, myocardial infarction, stroke, cancer, asthma, or chronic obstructive pulmonary disease, was assessed in WHII and FPS, and all-cause mortality was assessed in HBS. These outcomes were obtained from linked electronic health records in national health registries. Results: There were 23 149 participants, including 4118 men and women (median [IQR] age at first visit, 39 [37-42] years; 2968 men [72.1%]) from WHII, 2335 men (median [IQR] age at first visit, 42 [38-45] years) from HBS, and 16 696 men and women (median [IQR] age at first visit, 39 [34-43] years; 13 785 women [82.6%]) from FPS. During a median (IQR) follow-up of 22.8 (16.9-23.3) years, after adjusting for smoking, systolic blood pressure, and serum cholesterol at the first evaluation, WHII participants with weight loss had a decreased risk of developing chronic disease (hazard ratio [HR], 0.52; 95% CI, 0.35-0.78) compared with participants with persistent overweight. This finding was replicated after excluding diabetes from the outcome (HR, 0.58; 95% CI, 0.37-0.90). The corresponding HR in FPS was 0.43 (95% CI, 0.29-0.66) over a median (IQR) follow-up of 12.2 (8.2-12.2) years. In HBS, weight loss was associated with decreased mortality (HR, 0.81; 95% CI, 0.68-0.96) during an extended follow-up (median [IQR], 35 [24-43] years). Conclusions and Relevance: In this study, conducted when surgical and pharmacological weight-loss interventions were nearly nonexistent, sustained midlife weight loss compared with persistent overweight was associated with a decreased risk of chronic diseases beyond type 2 diabetes and decreased all-cause mortality.

Indexed as

Weight LossAdultBody Mass IndexCause of DeathChronic DiseaseCohort StudiesDiabetes Mellitus, Type 2FemaleFinlandFollow-Up StudiesHumansIncidenceMaleMiddle AgedRisk Factors

Identifiers

PMID40423973
PMCPMC12117462

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.